Analogue-based Drug Discovery III

Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs.
The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development.

Nyckelord: Molecular pharmacology, drug discovery, drug development, natural products, analogue-based drug discovery, analogue-based, pharmaceutical chemistry, IUPAC, medicinal chemistry, chemical classes, drug analogue development, János Fischer, C. Robin Ganellin, David Rotella, organic chemistry, pharmaceutical industry, international union of purere and applied chemistry, drug design, modification, competition in pharmaceutical drug development, metabolic stability, metabolism-guided drug design, macrocycles in drug design, Ulimorelin, ghrelin, gastrointestinal motility disorders, epigenetics, anticancer drugs, Thienopyridy, Direct-Acting P2Y12 Receptor Antagonist Antiplatelet Drugs, Selective Estrogen Receptor Modulators, Nonpeptide Vasopressin V2 Receptor Antagonists, Cysteinyl Leukotriene Receptor Antagonists, Dabigatran Etexilate, Citalopram, Escitalopram, Tapentadol, morphine, tramadol, Novel Taxanes, Cabazitaxel, Boceprevir, Narlaprevir, structure-based drug design, New-Generation Uric Acid Production Inhibitor, Febuxostat 365, Molecular Pharmacology, Natural Products, Molecular Pharmacology, Natural Products